BVF Inc. IL Invests $14.60 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

BVF Inc. IL purchased a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,237,556 shares of the company's stock, valued at approximately $14,595,000. BVF Inc. IL owned 26.42% of RAPT Therapeutics at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of RAPT. Picton Mahoney Asset Management lifted its position in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after buying an additional 14,697 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in RAPT Therapeutics by 9.2% during the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock worth $348,000 after purchasing an additional 18,558 shares during the period. JPMorgan Chase & Co. increased its stake in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after purchasing an additional 25,130 shares in the last quarter. Barclays PLC raised its position in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of RAPT Therapeutics by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock valued at $1,133,000 after buying an additional 33,758 shares in the last quarter. Hedge funds and other institutional investors own 99.09% of the company's stock.

RAPT Therapeutics Price Performance

NASDAQ RAPT traded down $0.04 during trading on Friday, reaching $0.76. The company's stock had a trading volume of 529,788 shares, compared to its average volume of 1,282,426. The stock has a market capitalization of $99.94 million, a PE ratio of -0.27 and a beta of -0.04. The firm has a fifty day moving average of $1.03 and a 200 day moving average of $1.26. RAPT Therapeutics, Inc. has a one year low of $0.75 and a one year high of $6.05.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23. Research analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.